A Phase I, Single-Arm, Single-Center Study to Investigate Safety and Reactogenicity of Monovalent Conjugated Vaccine Against Haemophilus Influenzae Type b in Healthy Children Aged 16 - 20 Months and Infants Aged 2 - 4 Months.
Phase of Trial: Phase I
Latest Information Update: 23 Apr 2013
At a glance
- Drugs TAK 816 (Primary)
- Indications Haemophilus infections
- Focus Adverse reactions
- 07 Feb 2012 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
- 07 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 08 Sep 2008 New trial record.